About Transgenomic (NASDAQ:PRPO)
Precipio, Inc., formerly Transgenomic, Inc., is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment. The Company is engaged in the provision of its Multiplexed ICE COLD-PCR (MX-ICP) product to the clinical market, enabling the use of blood and other bodily fluids for diagnosis, monitoring and treatment of cancer. MX-ICP amplifies the ability to detect genetic mutations by approximately 100 to 400 fold. MX-ICP is validated internally on sequencing platforms, including Sanger, Next Gen Sequencing and Digital polymerase chain reaction (PCR). Its laboratory in Omaha, Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:PRPO
- CUSIP: N/A
- Web: www.precipiodx.com
- Market Cap: $14.94 million
- Outstanding Shares: 8,121,000
- 50 Day Moving Avg: $2.02
- 200 Day Moving Avg: $4.84
- 52 Week Range: $1.51 - $20.00
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Net Margins: -536.28%
- Return on Assets: -108.93%
- Debt-to-Equity Ratio: 0.01%
- Current Ratio: 0.11%
- Quick Ratio: 0.10%
- Average Volume: 69,106 shs.
- Beta: 0.07
Frequently Asked Questions for Transgenomic (NASDAQ:PRPO)
What is Transgenomic's stock symbol?
Transgenomic trades on the NASDAQ under the ticker symbol "PRPO."
When did Transgenomic's stock split? How did Transgenomic's stock split work?
Transgenomic's stock reverse split before market open on Tuesday, June 6th 2017. The 1-30 reverse split was announced on Thursday, May 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Transgenomic stock prior to the reverse split would have 3 shares after the split.
How were Transgenomic's earnings last quarter?
Transgenomic, Inc. (NASDAQ:PRPO) released its quarterly earnings data on Friday, August, 12th. The company reported ($3.00) earnings per share (EPS) for the quarter. The business earned $0.51 million during the quarter. View Transgenomic's Earnings History.
Who are some of Transgenomic's key competitors?
Some companies that are related to Transgenomic include OncoSec Medical Incorporated (ONCS), Burcon NutraScience Corp (BUR), Repros Therapeutics (RPRX), Jaguar Animal Health (JAGX), OpGen (OPGN), Senestech (SNES), Oxford Pharmascience Group Plc (OXP), Novogen Limited (NVGN), RXi Pharmaceuticals Corp (RXII), Metabolix (YTEN), Ampliphi Biosciences Corp (APHB), Synairgen plc (SNG), Ixico Plc (IXI), Roka Bioscience (ROKA), Akers Biosciences (AKR), OncoGenex Pharmaceuticals (ACHV), Rosetta Genomics (ROSG) and Anacor Pharmaceuticals (ANAC).
Who are Transgenomic's key executives?
Transgenomic's management team includes the folowing people:
- Robert M. Patzig, Independent Chairman of the Board
- Ilan Danieli, President, Chief Executive Officer, Director
- Carl R Iberger, Chief Financial Officer
- Mark Rimer, Director
- Jeffrey Cossman, Independent Director
- Douglas Fisher M.D., Independent Director
- Michael A. Luther Ph.D., Independent Director
- Samuel D. Riccitelli, Independent Director
Who owns Transgenomic stock?
How do I buy Transgenomic stock?
Shares of Transgenomic can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Transgenomic's stock price today?
MarketBeat Community Rating for Transgenomic (NASDAQ PRPO)MarketBeat's community ratings are surveys of what our community members think about Transgenomic and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Transgenomic stock can currently be purchased for approximately $1.84.
Consensus Ratings for Transgenomic (NASDAQ:PRPO) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Transgenomic (NASDAQ:PRPO)
Analysts' Ratings History for Transgenomic (NASDAQ:PRPO)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Transgenomic (NASDAQ:PRPO)Earnings History by Quarter for Transgenomic (NASDAQ PRPO)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/12/2015||Q315||($8.10)||($5.40)||$6.65 million||$4.00 million||View||Listen|
|8/13/2015||Q215||($12.30)||($9.00)||$7.10 million||$7.00 million||View||Listen|
|5/14/2015||Q115||($15.60)||($10.80)||$6.80 million||$6.51 million||View||Listen|
|4/15/2015||Q414||($16.80)||($23.10)||$6.20 million||$7.70 million||View||N/A|
|10/30/2014||($17.40)||($18.30)||$6.80 million||$6.37 million||View||N/A|
|5/7/2014||($14.10)||($18.00)||$6.73 million||$6.25 million||View||N/A|
|3/12/2014||($10.80)||($1.50)||$6.71 million||$6.22 million||View||N/A|
Earnings Estimates for Transgenomic (NASDAQ:PRPO)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Transgenomic (NASDAQ:PRPO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Transgenomic (NASDAQ:PRPO)
Insider Ownership Percentage: 1.90%Insider Trades by Quarter for Transgenomic (NASDAQ:PRPO)
Institutional Ownership Percentage: 6.72%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/22/2014||Leroy C Kopp||Major Shareholder||Sell||413,050||$3.70||$1,528,285.00|| |
|10/2/2013||Leroy C Kopp||Major Shareholder||Buy||9,000||$0.39||$3,510.00|| |
Headline Trends for Transgenomic (NASDAQ:PRPO)
Latest Headlines for Transgenomic (NASDAQ:PRPO)
Loading headlines, please wait.
Transgenomic (PRPO) Chart for Sunday, October, 22, 2017